A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...
Among diabetes drugs, GLP-1 receptor agonists and SGLT2 inhibitors were associated with greater reduction in the risk for Alzheimer’s disease (AD) than DPP-4 inhibitors, new research showed. “GLP-1 ...
MedPage Today on MSN
Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk
Patterns differ among medication classes; potential mechanisms need more research ...
The landscape of diabetes management is undergoing a remarkable transformation. Groundbreaking research has uncovered surprising cardiovascular benefits tied to modern medications, offering new hope ...
A large McGill University study has found that two classes of medications commonly prescribed for type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. Drawing on ...
Hosted on MSN
Diabetes and dementia are far more tangled than doctors once believed, new research shows
Older adults with type 2 diabetes face a higher risk of dementia, but the connection between the two conditions runs deeper than average blood sugar levels. A cluster of recent studies, drawing on ...
(HealthDay)—No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds. The analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results